Pharmaceuticals, Biotechnology and Life Sciences
The LYRICA Pediatric Epilepsy Program is composed of six studies in
patients with epilepsy evaluating LYRICA as adjunctive therapy, five of
which have been completed.
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation SAN…
First-Quarter 2019 Revenues of $13.1 Billion, Reflecting 5% Operational Growth Driven by 7% Operational Growth from Pfizer Biopharmaceuticals Group and…
Pfizer has received positive opinion recommending TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor
Pfizer and Eli lilly have announced top-line results from a Phase 3 study evaluating tanezumab 2.5mg and 5 mg.
DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral,…
Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront
Approval of expanded indication based predominately on real-world data NEW YORK–(BUSINESS WIRE)–Pfizer (NYSE:PFE) today announced that the U.S. Food and…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor…
German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.